Insulin glargine: A new basal insulin

Annals of Pharmacotherapy

Volumn 36, Issue 6, 2002, Pages 1019-1027

  Levien, Terri L ^a   Baker, Danial E ^a   White Jr , John R ^a   Campbell, R Keith ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Insulin glargine; Lantus

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DANAZOL; DEXTROPROPOXYPHENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUOXETINE; GROWTH HORMONE; INSULIN GLARGINE; INSULIN LISPRO; ISONIAZID; ISOPHANE INSULIN; LEVOTHYROXINE; LIOTHYRONINE; MONOAMINE OXIDASE INHIBITOR; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PENTAMIDINE; PHENOTHIAZINE DERIVATIVE; SALBUTAMOL; SALICYLIC ACID; SULFONAMIDE; UNINDEXED DRUG; DRUG DERIVATIVE; GLARGINE; INSULIN;

ACIDITY; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL LITERATURE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STRUCTURE ANALYSIS; AMINO ACID SEQUENCE; CLASSIFICATION; DIABETES MELLITUS; DRUG ADMINISTRATION; DRUG INTERACTION; META ANALYSIS; PHARMACOECONOMICS; REVIEW;

AMINO ACID SEQUENCE; CLINICAL TRIALS; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ECONOMICS, PHARMACEUTICAL; HUMANS; INSULIN;

EID: 0036014073     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A301     Document Type: Article

References (41)

1. Long-acting insulin analogs
2. Clinical pharmacology of human insulin
3. New approaches to the treatment of diabetes
4. Insulin analogs with improved pharmacokinetic profiles
5. European Study Group of HOE 901 in Type 1 Diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes
6. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin
7. IGF-I receptor-mediated signalling of the human insulin analogue HOE 901
8. B31]insulin (HOE 901) in muscle cells
9. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
10. In vitro pharmacology studies with insulin glargine and human insulin: IGF-1 receptor binding and thymidine incorporation, abstract 1787-PO
11. Effects of insulin glargine, human insulin and the insulin analog Asp(B10) on the insulin receptor signaling cascade, abstract 525-P
12. Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE1) in T1DM
13. 24 h profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology
14. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
15. Pharmacokinetics of a 'long-acting' human insulin analogue (HOE901) in healthy subjects
16. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro
17. Time-action profile of insulin glargine (HOE901) in Japanese volunteers
18. 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different injection sites
19. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects
20. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
21. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus[reg]) compared to BID NPH in subjects with type 1 diabetes
22. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
23. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type I diabetes mellitus without increasing the risk of hypoglycemia
24. Less nocturnal hypoglycemia and better post-dimer glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
25. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin
26. Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus[reg]) compared to bedtime NPH insulin in patients with type 2 diabetes
27. Treatment satisfaction and psychological well-being in patients with type 1 diabetes, treated with a new long-acting insulin glargine
28. Treatment satisfaction and psychological well-being in patients with type 1 diabetes, treated with a new long-acting insulin glargine
29. Efficacy and safety of HOE 901 in patients with type 1 DM: A four-week randomized, NPH insulin-controlled trial
30. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
31. Comparison of insulin glargine (HOE901) vs. NPH insulin during 1 year of insulin combination therapy in type 2 diabetes
32. The effect of HOE 901 on glycemic control in type 2 diabetes
33. Comparative clinical trial of a new long-acting insulin (HOE901) vs. protamine insulin demonstrates less nocturnal hypoglycaemia
34. Effects of insulin glargine on hypoglycemia awareness and counterregulation
35. Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine
36. Diabetic retinopathy in patients with type 1 diabetes treated with insulin glargine or NPH
37. Insulin analogues and their potential in the management of diabetes mellitus